Objective. Recently, our group conceived a risk score for clinical manifestations of APS (the global APS score, or GAPSS) that takes into account the combination of independent cardiovascular risk factors and the aPL positivity profile. These include hyperlipidaemia, arterial hypertension, aCL, anti-b2 glycoprotein-I, aPS-PT and the LA.
Introduction
APS is the most common acquired thrombophilia, an autoimmune disorder characterized by arterial and/or venous thrombosis and/or pregnancy morbidity in the presence of persistent positivity for aPL [1] . The current classification criteria for APS include three laboratory tests: LA, aCL and anti-b2 glycoprotein-I (anti-b2GPI).
To prevent the detection of transient antibodies, tests must be positive on more than two occasions, at least 12 weeks apart [1] .
Identifying patients with aPL who are at higher risk for developing any clinical manifestations of APS (thrombotic and/or pregnancy morbidity) is still an unmet clinical need and remains a major challenge in routine clinical practice. Recently, our group conceived a risk score for clinical manifestations of APS (the global APS score, or GAPSS) that takes into account the combination of independent cardiovascular risk factors and the aPL positivity profile. These include hyperlipidaemia, arterial hypertension, aCL, anti-b2GPI, aPS-PT and the LA [2] . Despite the amount of data supporting the usefulness of aPS-PT as a diagnostic and prognostic biomarker, these antibodies are not included as laboratory criteria for APS and therefore, although they are available, are still not routinely used in the clinical setting [3] . For this reason, a complementary version, the adjusted GAPSS (aGAPSS), which excludes aPS-PT, was also designed. The aim of our study was to systematically review the literature to assess the clinical utility of the GAPSS and aGAPSS for risk stratification of any APS clinical manifestation.
Methods

Literature search
A detailed literature search has been developed a priori to identify articles that reported findings from clinical and laboratory studies that demonstrated the clinical utility of GAPSS or aGAPSS. Key words and subject terms included: Studies that met the criteria to evaluate the clinical utility of GAPSS or aGAPSS and their association with clinical manifestations of APS in patients and control populations were systematically analysed by two independent reviewers (M.R. and I.C.). Disagreements were resolved by consensus; if consensus could not be achieved, a third party (S.S.) would provide an assessment of eligibility. As the data on eligibility were dichotomous (eligible: yes/no), inter-rater agreement at both the title and abstract review and the full article review stages was determined by calculation of Cohen's k coefficient (k = 0.93).
We included in our analysis only studies reporting: clinical data referring to aPL-related manifestations; laboratory data including aCL, LA, anti-b2GPI and/or aPS-PT testing; studies reporting the GAPSS and aGAPSS in the different populations reported in the analysis. All published series including 10 or more patients meeting the above inclusion criteria were recorded. Methods of enrolment were also analysed. The present study has been performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [4] .
Statistical analysis
Cumulative GAPSS was calculated as the weighted average when means and S.D. were provided from the included studies for each study group.
The significance of baseline differences between groups was determined by the unpaired t-test. A twosided P < 0.05 was statistically significant. All statistical analyses were performed using SPSS version 19.0 (IBM, Armonk, NY, USA).
Results
A total of 10 studies [2, 513] , including 2273 patients, met the inclusion criteria. Study characteristics and patients enrolled are summarized in Table 1 . In brief, we retrieved one cross-sectional study (including 105 patients), seven retrospective analyses (1980 patients) and two prospective studies (188 patients).
Seven studies [2, 510] used the GAPSS in their cohort, whereas three studies [1113] used the aGAPSS. For the studies that used the GAPSS, six studies [2, 58, 10] including a total of 1187 patients were found to be eligible to calculate a cumulative GAPSS for different clinical manifestations of APS.
In brief, we found a statistically significant difference in the cumulative GAPSS between patients that experienced an arterial and/or venous thrombotic event [cumulative GAPSS 10.6 (4.74)], patients without any thrombotic manifestation [cumulative GAPSS 7.01 (5.46)] and patients with pregnancy morbidity [cumulative GAPSS 8.79 (2.59)]. Data comparing the GAPSS and aGAPSS in the different cohort of patients are summarized in Fig. 1 and Table S1 , available as supplementary data at Rheumatology online.
The highest levels of GAPSS were found in patients that experienced arterial thrombosis [mean GAPSS 12.2 (5.2)] and patients that experienced any recurrences of clinical manifestations of APS, including thrombosis and/or pregnancy morbidity [mean GAPSS 13.7 (3.1)].
When analysing the studies that assessed the risk of clinical manifestations of APS using the aGAPSS, all three studies were found eligible for calculating the cumulative aGAPSS between cohorts. Similar to the study that used the GAPSS, we found a statistically significant difference between patients that experienced an arterial and/or venous thrombotic event [cumulative aGAPSS 7.6 (3.95)], patients without any thrombotic manifestation [cumulative aGAPSS 4.9 (4.33)] and patients with pregnancy morbidity [cumulative aGAPSS 6.7 (2.8)].
Discussion
Risk stratification is one of the fundamentals of current medical research, aiming to identify individuals who have a high risk of developing an adverse outcome over a specific time period, so that they can be targeted for early preventative strategies and possible treatments. Prediction models have been widely developed for cardiovascular diseases [14, 15] , with most of them focusing on cardiac or cerebrovascular events.
Recently, three score systems have been formulated to quantify the risk of thrombosis/obstetric events in subjects with aPL, with or without clinical evidence of confirmed APS, in an attempt to help physicians to stratify patients according to risk [2, 16, 17] . The first two scores [16, 17] focus on aPL profile, while the most recently developed one, the GAPSS [2] , also includes cardiovascular risk factors when computing the risk.
In this systematic review, we aimed to collect available evidence on the clinical relevance of the GAPSS. When analysing together data from 2273 patients, we found that the GAPSS is a valid tool to stratify patients with aPL according to their thrombotic risk, the highest levels of GAPSS being found in patients who experienced thrombosis, especially arterial thrombosis. Interestingly, the GAPSS has also been proven to identify patients at higher likelihood of developing further events, as patients who suffered from any recurrences of clinical manifestations of APS showed higher value of GAPSS when compared with those who did not.
The presence of aPS-PT has been associated with thrombosis in APS [18] and testing for these antibodies has been shown to improve the diagnostic accuracy when APS is suspected [19] . Although aPS-PT testing is now more widely available [20] , this test is still not included among the criteria for aPL and not all laboratories routinely test for aPS-PT. For this reason, a complementary version, the adjusted GAPSS or aGAPSS, which excludes aPS-PT, was also designed. Similar results to those found with the GAPSS were seen when applying the aGAPSS.
We acknowledge that our study has some limitations. First, despite the systematic nature of this review, combining heterogeneous studies (i.e. heterogeneous enrolled populations) might lead to shortcomings in the interpretation of the results. Including only studies from unselected patients (regardless of the underlying autoimmune status) would provide conclusions that are more generalizable. However, to the best of our knowledge, such studies are not available and therefore, this combination of studies from patients both with and without underlying autoimmune diseases provided us with larger number of patients, allowing for meaningful calculation of the estimates. Secondly, the information that could potentially increase the accuracy of the risk estimation, including adjustments for clinical or historical factors, treatments, physical examination findings, the timing of the GAPSS computation when referred to the clinical manifestation onset and other diagnostic test results, was rarely reported in the analysed studies.
In contrast, the strength of GAPSS, when compared with the previously proposed scores, lies in the inclusion of conventional cardiovascular risk factors into the computation.
In summary, this study, while having limitations, contains some important clinical messages: GAPSS may represent a useful tool to assess the thrombosis or pregnancy loss risk in aPL-positive patients, switching from the concept of aPL as a sole diagnostic antibody to aPL as a risk factor for clinical events. A risk assessment, using appropriate tools such as GAPSS, should be implemented to identify and monitor those patients at a higher risk of recurrence and those needing a strict control of all modifiable risk factor for cardiovascular events; as a result, in the future the management of APS should also modulate according to the GAPSS values. 
FIG. 1 Cumulative global APS score values between groups
GAPSS: global APS score; aGAPSS: adjusted global APS score; PM: pregnant morbidity.
